EQUETRO
Clinical safety rating: caution
Comprehensive clinical and safety monograph for EQUETRO (EQUETRO).
Equetro (carbamazepine extended-release) is an anticonvulsant and mood stabilizer. It stabilizes the inactivated state of voltage-gated sodium channels, thereby inhibiting repetitive neuronal firing and reducing synaptic transmission. It also potentiates GABA receptors and inhibits glutamate release.
| Metabolism | Primarily hepatic via CYP3A4 to carbamazepine-10,11-epoxide (active metabolite); also metabolized by CYP2C8 and UGT2B7. Autoinduction of its own metabolism occurs. |
| Excretion | Renal: 2% excreted unchanged (carbamazepine) in urine; 15% as carbamazepine-10,11-epoxide; 30% as other metabolites; biliary/fecal: 50-60% as metabolites. |
| Half-life | Carbamazepine: 25-65 hours (initial single dose), 12-17 hours (chronic dosing due to autoinduction); carbamazepine-10,11-epoxide: 5-8 hours. |
| Protein binding | 75-90% bound to albumin and alpha1-acid glycoprotein (carbamazepine); 50% bound (epoxide metabolite). |
| Volume of Distribution | 0.8-2.0 L/kg (total carbamazepine); higher in neonates and children; reflects extensive tissue distribution and CNS penetration. |
| Bioavailability | Extended-release oral: 75-85% compared to immediate-release (due to slower absorption and reduced first-pass metabolism). |
| Onset of Action | Extended-release oral: 4-8 hours for initial effect; therapeutic steady state achieved in 2-4 weeks. |
| Duration of Action | Extended-release oral: 12-24 hours per dose (maintenance of therapeutic levels); clinical effect sustained with twice-daily dosing. |
| Molecular Weight | 144.21 |
Initial: 50 mg orally twice daily; increase by 50-100 mg/day every 2-4 weeks. Usual maintenance: 100-200 mg orally twice daily. Maximum: 200 mg orally twice daily.
| Dosage form | CAPSULE, EXTENDED RELEASE |
| Renal impairment | GFR 30-89 mL/min: No adjustment required. GFR 15-29 mL/min: Reduce dose by 50%. GFR <15 mL/min: Use with caution; reduce dose by 75% or consider alternative. |
| Liver impairment | Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 50%. Child-Pugh Class C: Use with caution; reduce dose by 75% and monitor closely. |
| Pediatric use | Not approved for patients <18 years. Safety and efficacy not established. |
| Geriatric use | Start at low end of dosing range (50 mg twice daily), titrate slowly due to increased risk of renal impairment and drug accumulation. |
| 1st trimester | EQUETRO (valproate semisodium) is contraindicated in the first trimester due to high risk of neural tube defects (3-5%) and other major malformations (10-15%). |
| 2nd trimester | Avoid use in second trimester; increased risk of neurodevelopmental delay and other congenital anomalies persists. |
| 3rd trimester | Avoid use in third trimester; risk of maternal bleeding, hepatic toxicity, and neonatal withdrawal syndrome. Use only if no alternative and benefit outweighs risk. |
Clinical note
Comprehensive clinical and safety monograph for EQUETRO (EQUETRO).
| Placental transfer | Valproate crosses the placenta readily with fetal serum concentrations reaching 50-100% of maternal levels. Active transport via monocarboxylate transporter 1 (MCT1) contributes to accumulation in fetal brain. |
| Breastfeeding | Valproate is excreted into breast milk at low levels (1-10% of maternal serum concentration). No adverse effects reported in typical doses, but monitor infant for drowsiness, thrombocytopenia, and hepatic dysfunction. Benefit of breastfeeding likely outweighs minimal risk. |
■ FDA Black Box Warning
Serious dermatologic reactions including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), particularly in patients with the HLA-B*1502 allele. Aplastic anemia and agranulocytosis may occur; obtain baseline CBC and monitor frequently.
| Serious Effects |
Pregnancy (first trimester and all trimesters for bipolar disorder)Active liver disease or severe hepatic impairmentKnown hypersensitivity to valproate or derivativesUrea cycle disordersMitochondrial disease (POLG mutation)Women of childbearing potential unless effective contraception is used and pregnancy is excluded
| Precautions | Hematologic toxicity (monitor CBC), dermatologic reactions (SJS/TEN), hypersensitivity syndrome, exacerbation of seizures (if not titrated slowly), hyponatremia (SIADH), hepatic effects, glaucoma (increases intraocular pressure), and cognitive impairment. |
| Food/Dietary | Grapefruit juice: May increase carbamazepine levels, increasing toxicity risk. Avoid concurrent consumption. Alcohol: May enhance CNS depression and increase seizure risk. High-fat meals: May affect absorption of extended-release formulation; consistent timing with meals recommended. |
Loading safety data…
| Lactation Rating | L2 (limited data / probably compatible) |
| Teratogenic Risk | EQUETRO (carbamazepine) is classified as FDA Pregnancy Category D. First trimester exposure increases risk of neural tube defects (e.g., spina bifida) approximately 1-2% above baseline. Craniofacial defects, fingernail hypoplasia, and developmental delay are associated. Second and third trimester exposure may cause neonatal withdrawal, vitamin K deficiency (hemorrhagic disease), and transient hepatic dysfunction. Antiepileptic Drug Pregnancy Registry data confirm increased major congenital malformations. |
| Fetal Monitoring | Monitor serum carbamazepine levels (therapeutic range 4-12 mcg/mL) every 4-8 weeks during pregnancy due to increased clearance. Fetal ultrasound at 18-20 weeks for neural tube defects. Assess maternal folate levels; supplement with 4-5 mg/day folic acid preconception and throughout first trimester. Monitor maternal liver function tests, CBC with platelets, and thyroid function. Neonatal monitoring for withdrawal symptoms, coagulation (administer vitamin K immediately after birth), and hepatic function. |
| Fertility Effects | Carbamazepine may induce hepatic cytochrome P450 enzymes, increasing clearance of sex steroids. This can reduce efficacy of hormonal contraceptives and potentially cause menstrual irregularities (anovulation, oligomenorrhea) through altered estrogen/progesterone metabolism. While not directly impairing fertility, these effects may complicate conception timing. In men, carbamazepine has been associated with decreased sperm count and motility, though reversibility is likely upon discontinuation. |
| Clinical Pearls | EQUETRO (carbamazepine extended-release) is an antiepileptic drug with mood-stabilizing properties. Use caution when switching from immediate-release formulations; dosing adjustments may be needed. Monitor for hyponatremia, especially in elderly patients or those on diuretics. Induction of CYP3A4 can reduce efficacy of oral contraceptives, warfarin, and many other drugs. Contraindicated in patients with bone marrow depression, porphyria, or history of hypersensitivity to tricyclic antidepressants. |
| Patient Advice | Do not crush, chew, or break the extended-release capsule; swallow whole with liquid. · Take with food to reduce stomach upset. · Avoid alcohol and grapefruit juice as they may affect drug levels. · Report signs of liver toxicity (jaundice, dark urine) or blood dyscrasias (fever, sore throat, easy bruising) immediately. · Use effective non-hormonal contraception due to reduced efficacy of birth control pills. · Do not stop abruptly; taper under medical supervision to avoid withdrawal seizures. |